The study of fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant liver tumor

The study of fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant liver tumor - Five-aminolevulinic acid for fluorescence-guided resection of malignant liver tumor

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000011136

Enrollment

Registered

2013-07-06

Start date

2013-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

malignant liver tumor

Interventions

5ALA oral intake

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who meet all of the requirements described below are included. 1.Patients who are hospitalized at Kansai Medical university Hirakata hospital in order to undergo surgery. 2.Patients who are diagnosed with malignant liver tumor. 3.Patients who provide a written informed consent.

Exclusion criteria

Exclusion criteria: Patients who meet any of the conditions described below are excluded. 1.Patients with porphyria. 2.Patients with hypersensitivity to 5-ALA or porphyrins. 3.In cases of known or suspected pregnancy or woman who are breast-feeding. 4.In cases of hepatic insufficiency (total bilirubin >2.4mg/dL, AST>70U/L, ALT>70U/L) on post 1 and 7 days after taking 5-ALA before 2 weeks of surgery.

Design outcomes

Primary

Measure	Time frame
resection rate	—

Countries

Japan

Contacts

Public ContactKosuke Matsui

Kansai Medical University Hirakata Hospital Surgery

matsuik@hirakata.kmu.ac.jp072-804-0101

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026